124 related articles for article (PubMed ID: 2353797)
1. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis.
Bever CT; Leslie J; Camenga DL; Panitch HS; Johnson KP
Ann Neurol; 1990 Apr; 27(4):421-7. PubMed ID: 2353797
[TBL] [Abstract][Full Text] [Related]
2. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis.
Davis FA; Stefoski D; Rush J
Ann Neurol; 1990 Feb; 27(2):186-92. PubMed ID: 2317014
[TBL] [Abstract][Full Text] [Related]
3. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
Cornblath DR; Bienen EJ; Blight AR
Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
[TBL] [Abstract][Full Text] [Related]
4. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis.
Polman CH; Bertelsmann FW; de Waal R; van Diemen HA; Uitdehaag BM; van Loenen AC; Koetsier JC
Arch Neurol; 1994 Nov; 51(11):1136-9. PubMed ID: 7980110
[TBL] [Abstract][Full Text] [Related]
5. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
Korenke AR; Rivey MP; Allington DR
Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
[TBL] [Abstract][Full Text] [Related]
6. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.
Judge SI; Bever CT
Pharmacol Ther; 2006 Jul; 111(1):224-59. PubMed ID: 16472864
[TBL] [Abstract][Full Text] [Related]
7. Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Goodman AD; Brown TR; Cohen JA; Krupp LB; Schapiro R; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Neurology; 2008 Oct; 71(15):1134-41. PubMed ID: 18672472
[TBL] [Abstract][Full Text] [Related]
8. An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy?
De Cauwer H; De Wolf P; Couvreur F; Mortelmans L
Acta Neurol Belg; 2009 Mar; 109(1):40-1. PubMed ID: 19402572
[TBL] [Abstract][Full Text] [Related]
9. Sustained release oral fampridine in the treatment of multiple sclerosis.
Kachuck NJ
Expert Opin Pharmacother; 2009 Aug; 10(12):2025-35. PubMed ID: 19586420
[TBL] [Abstract][Full Text] [Related]
10. 4-Aminopyridine improves clinical signs in multiple sclerosis.
Stefoski D; Davis FA; Faut M; Schauf CL
Ann Neurol; 1987 Jan; 21(1):71-7. PubMed ID: 2435223
[TBL] [Abstract][Full Text] [Related]
11. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis.
Sheean GL; Murray NM; Rothwell JC; Miller DH; Thompson AJ
Brain; 1998 May; 121 ( Pt 5)():967-75. PubMed ID: 9619197
[TBL] [Abstract][Full Text] [Related]
12. The current status of studies of aminopyridines in patients with multiple sclerosis.
Bever CT
Ann Neurol; 1994; 36 Suppl():S118-21. PubMed ID: 8017870
[TBL] [Abstract][Full Text] [Related]
13. [Aminopyridines for symptomatic treatment of multiple sclerosis].
Jensen HB; Stenager E; Ravnborg MH
Ugeskr Laeger; 2011 Dec; 173(50):3259-63. PubMed ID: 22153210
[TBL] [Abstract][Full Text] [Related]
14. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
Goodman AD; Cohen JA; Cross A; Vollmer T; Rizzo M; Cohen R; Marinucci L; Blight AR
Mult Scler; 2007 Apr; 13(3):357-68. PubMed ID: 17439905
[TBL] [Abstract][Full Text] [Related]
15. Sustained-release fampridine for multiple sclerosis.
Bever CT; Judge SI
Expert Opin Investig Drugs; 2009 Jul; 18(7):1013-24. PubMed ID: 19548855
[TBL] [Abstract][Full Text] [Related]
16. No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.
Lorenz D; Hagen K; Ufer M; Cascorbi I; Deuschl G; Volkmann J
Neurology; 2006 Jun; 66(11):1753-5. PubMed ID: 16769957
[TBL] [Abstract][Full Text] [Related]
17. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
[TBL] [Abstract][Full Text] [Related]
18. Dalfampridine (Ampyra) for MS.
Med Lett Drugs Ther; 2010 Sep; 52(1347):73-4. PubMed ID: 20847716
[No Abstract] [Full Text] [Related]
19. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial.
Bever CT; Anderson PA; Leslie J; Panitch HS; Dhib-Jalbut S; Khan OA; Milo R; Hebel JR; Conway KL; Katz E; Johnson KP
Neurology; 1996 Dec; 47(6):1457-62. PubMed ID: 8960727
[TBL] [Abstract][Full Text] [Related]
20. 3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study.
Flet L; Polard E; Guillard O; Leray E; Allain H; Javaudin L; Edan G
J Neurol; 2010 Jun; 257(6):937-46. PubMed ID: 20058019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
